论文部分内容阅读
目的研究卵巢癌患者血清中HE4和CA125水平,为卵巢癌的临床诊断和鉴别诊断提供参考。方法分别用ELISA和电化学发光法检测121例妇女血清中HE4和CA125水平。其中78例盆腔肿瘤患者按术后病理结果分为卵巢癌组(n=27)和良性病变组(n=51);43例体检健康妇女作为正常对照组(n=43)。综合评价HE4和CA125联合检测的临床价值。结果卵巢癌组HE4和CA125水平分别为(581.5±445.7)PM/L和(817.5±534.4)U/L;良性病变组HE4和CA125水平分别为(51.4±22.9)PM/L和(84.5±78.9)U/L;正常对照组HE4和CA125水平分别为(36.7±12.0)PM/L和(18.9±9.3)U/L。HE4诊断卵巢癌的敏感性和特异性分别为66.7%和98.0%;CA125诊断卵巢癌的敏感性和特异性分别为88.9%和78.4%。结论血清HE4和CA125水平检测是诊断卵巢癌的良好指标,HE4单项检测的特异度优于CA125单项检测,二者联合检测可以提高诊断能力。
Objective To study the serum levels of HE4 and CA125 in patients with ovarian cancer and provide a reference for the clinical diagnosis and differential diagnosis of ovarian cancer. Methods The serum levels of HE4 and CA125 in 121 women were detected by ELISA and electrochemiluminescence, respectively. Among them, 78 cases of pelvic tumor were divided into ovarian cancer group (n = 27) and benign lesion group (n = 51) according to the postoperative pathological results. Forty-three healthy women as normal control group (n = 43). Comprehensive evaluation of HE4 and CA125 combined detection of clinical value. Results The levels of HE4 and CA125 in ovarian cancer group were (581.5 ± 445.7) PM / L and (817.5 ± 534.4) U / L, respectively. The levels of HE4 and CA125 in the benign group were (51.4 ± 22.9) PM / L and ) U / L; The levels of HE4 and CA125 in the normal control group were (36.7 ± 12.0) PM / L and (18.9 ± 9.3) U / L, respectively. The sensitivity and specificity of HE4 in the diagnosis of ovarian cancer were 66.7% and 98.0%, respectively. The sensitivity and specificity of CA125 in diagnosing ovarian cancer were 88.9% and 78.4%, respectively. Conclusion The detection of serum HE4 and CA125 levels is a good indicator for the diagnosis of ovarian cancer. The specificity of single HE4 test is better than single test of CA125, and the combined detection of HE4 and CA125 can improve the diagnostic ability.